RTI-HS Researchers Outline Best Practices for Collecting Patient Experience Data During the COVID-19 Outbreak

Share on: 

Experts on our Patient-Centered Outcomes Assessment (PCOA) team collaborated to create this best practices document to help research teams mitigate some of the impacts of COVID-19 on the collection and use of clinical outcome assessment (COA) data. They drew on current FDA recommendations for patient-focused drug development (PFDD) and other more emergent regulatory commentaries specific to COVID-19, as well as guidance from sources outside the US such as the MHRA and HRA in the UK and, more broadly for the EU, the EMA. The document provides guidance on determining go/no go decisions, understanding potential threats to study validity, and alternative methods for capturing patient experience data.

For additional information or to learn more about how we can assist you with patient experience data collection, contact one of our experts using the links below.

 
(no registration required)

Related Services:
Staff Members: